After Travere Therapeutics (TVTX) announced that the FDA informed the company it no longer plans to hold an advisory committee meeting to review the sNDA for Filspari for focal segmental glomerulosclerosis, BofA analyst Jason Zemansky notes that shares are up pre-market and says the news should reassure investors about approval. With the FDA’s update arguably strengthening the outlook for approval by the PDUFA date of January 13, the firm sees potential for the “next leg of growth for Filspari,” says the analyst, who maintains a Buy rating and $29 price target on Travere shares.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on TVTX:
- FDA Drops Advisory Committee for Travere’s FILSPARI Review
- FDA says advisory committee no longer needed for Travere Filspari sNDA
- Optimistic Outlook for Travere Therapeutics Driven by Regulatory Advancements and Market Opportunities
- Nvidia reports Q2 beat, Snowflake posts ‘beat and raise’: Morning Buzz
- Ligand price target raised to $206 from $157 at H.C. Wainwright